Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108-ADC in c-Met positive advanced solid tumors
NCT04617314Phase 1Completed
- Sponsor
- RemeGen
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RC108 in solid tumor, sponsored by RemeGen. Primary endpoints: Adverse Events and Maximum Tolerated Dose at 21 days. Started Mar 2021; status: completed.
02
Drugs
RC108
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04617314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617314.